A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Sponsor
Feng Wang
Study ID
NCT06682247
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Colorectal Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Key Dates

First listed
Nov 12, 2024
Start date
Nov 15, 2024
Status verified
Nov 2024
Primary completion
Jun 15, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: chidamide + PD-1/PD-L1 inhibitors +Bevacizumab or tyrosine kinase inhibitors

Primary Outcome Measure

Progression-free survival(PFS) [ Time Frame: 2 years ]

Central Contacts

Related Studies